FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
 
 
TXT Gorsuch Likely to Maintain Preemption Jurisprudence: Lawyers
06/21/2017
 
 
TXT Voluntary Drug Quality Metrics Reporting Begins 2018
06/22/2017
 
 
TXT Public Citizen Rebuffs Draft Pharma Executive Order
06/23/2017
 
 
TXT FDA/EMA Pilot Program Aims to Harmonize Inspections
06/21/2017
 
 
TXT Gottlieb Pledges Revamp on Targeted Drug Development/Reviews
06/20/2017
 
 
TXT Pharmakon Employees Charged in Drug Potency Case
06/23/2017
 
 
TXT Support for FDA Patient Engagement Plans
06/21/2017
 
 
TXT FDA Opens Drug Continuous Manufacturing Docket
06/22/2017
 
 
TXT Compounded Drug Access Bill Introduced
06/21/2017
 
 
TXT FDA Public Meeting on Generic Drug Barriers
06/21/2017
 
 
TXT Critics Question Trump Drug Price Control Plan
06/21/2017
 
 
TXT Growing Industry Interest in Emerging Technologies: CDER
06/21/2017
 
 
TXT Product Approval Summaries
06/25/2017
 
 
TXT Latest Federal Register Notices
06/25/2017
 
 
TXT Since Our Last Issue ...
06/25/2017
 
 
TXT MAPP on NDA/BLA Financial Disclosure
06/22/2017
 
 
TXT Generic Drug Bioequivalence Study MAPP
06/22/2017
 
 
TXT Suits Against Drug Companies Scare Patients: Survey
06/22/2017
 
 
TXT Vascular Solutions Recalls Venture Catheter
06/21/2017
 
 
TXT FDA Advisors Support Victoza sNDA
06/21/2017
 
 
TXT Latest FDA Warning Letters
06/20/2017
 
 
TXT CGMP Violations at Qinhuangdao Zizhu
06/20/2017
 
 
TXT Guidance on Electronic Signatures in Clinical Investigations
06/20/2017
 
 
TXT Zimmer Biomet FDA-483 Response
06/20/2017
 
 
TXT Datascope Field Correction of Intra-Aortic Pumps
06/19/2017
 
 
TXT Seattle Genetics Stops Phase 3 Study Due to Deaths
06/19/2017
 
 
TXT FDA Draft Guide on ANDA Facility Pre-submissions
06/19/2017
 
 
 
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving